Quantitative Automated Analysis of Cancer Markers

Information

  • Research Project
  • 6553880
  • ApplicationId
    6553880
  • Core Project Number
    R43CA097911
  • Full Project Number
    1R43CA097911-01
  • Serial Number
    97911
  • FOA Number
    PAR-01-062
  • Sub Project Id
  • Project Start Date
    9/30/2002 - 22 years ago
  • Project End Date
    3/31/2004 - 20 years ago
  • Program Officer Name
    LIVELY, TRACY (LUGO)
  • Budget Start Date
    9/30/2002 - 22 years ago
  • Budget End Date
    3/31/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/30/2002 - 22 years ago
Organizations

Quantitative Automated Analysis of Cancer Markers

The overall goal of this project is to develop systems that both 1) provide quantitative data for diagnostic/prognostic/predictive profiling in breast cancer and 2) detect micrometastases in lymph nodes and other tissue. The Ikonisys technology platform enables automated analysis of tests based on in situ hybridization and immunohistochemistry (IHC), providing quantitative data on amplification and/or expression of marker genes even in "rare" cells in a pathological sample. The Phase I project focuses on demonstrating the utility of the system using fluorescence in situ hybridization (FISH) to detect amplification of c-erbB-2; gene amplification has been shown to be a better prognostic/predictive indicator than protein overexpression for this important breast cancer marker. The detection and analysis system will be tested using 1) a commercially available c-erbB-2 FISH assay and 2) proprietary probes for c-erbB-2 and chromosome 17q (an internal control for aneuploidy). Validation experiments will be performed on clinical samples obtained by mammary excision and ductal lavage. The Phase II project will optimize the system for analysis of other breast cancer markers detected by in situ hybridization and IHC, then test its ability to aid in predicting clinical outcomes in breast cancer patients and detect micrometastases in lymph node tissue.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    107000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:107000\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IKONISYS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    NEW HAVEN
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    065111966
  • Organization District
    UNITED STATES